Inovio reports preclinical results for H7N9 vaccine
Inovio, a pharmaceutical company based in Blue Bell, Pa., today announced the first preclinical results from tests in mice on its candidate DNA vaccine against the H7N9 virus, according to a press release.
The study was conducted by researchers at the University of Pennsylvania and Canada's National Microbiology Laboratory in Winnipeg.